116 related articles for article (PubMed ID: 17016771)
1. Obesity drug development - CBI's 2nd Annual Summit.
Heal DJ
IDrugs; 2006 Oct; 9(10):682-5. PubMed ID: 17016771
[No Abstract] [Full Text] [Related]
2. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
Ducobu J; Sternon J
J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
[TBL] [Abstract][Full Text] [Related]
3. End of the line for cannabinoid receptor 1 as an anti-obesity target?
Jones D
Nat Rev Drug Discov; 2008 Dec; 7(12):961-2. PubMed ID: 19043439
[TBL] [Abstract][Full Text] [Related]
4. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.
Xie S; Furjanic MA; Ferrara JJ; McAndrew NR; Ardino EL; Ngondara A; Bernstein Y; Thomas KJ; Kim E; Walker JM; Nagar S; Ward SJ; Raffa RB
J Clin Pharm Ther; 2007 Jun; 32(3):209-31. PubMed ID: 17489873
[TBL] [Abstract][Full Text] [Related]
5. Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
Doggrell SA
Expert Opin Pharmacother; 2005 Oct; 6(12):2141-4. PubMed ID: 16197364
[No Abstract] [Full Text] [Related]
6. [Rimonabant (Acomplia)].
Duh D; Vanddevijver A
J Pharm Belg; 2008 Mar; 63(1):27-8. PubMed ID: 18479080
[No Abstract] [Full Text] [Related]
7. [Selective cannabinoid receptor antagonists].
Kreutz S; Korf HW; Schubert-Zsilavecz M
Pharm Unserer Zeit; 2006; 35(6):512-20. PubMed ID: 17137082
[No Abstract] [Full Text] [Related]
8. [Endocannabinoid and endocannabinoid receptor antagonists].
Heinzl S
Med Monatsschr Pharm; 2005 Feb; 28(2):40-3. PubMed ID: 15727333
[No Abstract] [Full Text] [Related]
9. Drug development. Drugs inspired by a drug.
Marx J
Science; 2006 Jan; 311(5759):322-5. PubMed ID: 16424309
[No Abstract] [Full Text] [Related]
10. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.
Ward SJ; Raffa RB
Obesity (Silver Spring); 2011 Jul; 19(7):1325-34. PubMed ID: 21475141
[No Abstract] [Full Text] [Related]
11. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
Di Marzo V
Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695
[No Abstract] [Full Text] [Related]
12. Rimonabant and progression of atherosclerosis in obese persons.
Dora JM; Scheffel RS
JAMA; 2008 Jul; 300(3):280; author reply 280-1. PubMed ID: 18632538
[No Abstract] [Full Text] [Related]
13. Endocannabinoid control of food intake and energy balance.
Di Marzo V; Matias I
Nat Neurosci; 2005 May; 8(5):585-9. PubMed ID: 15856067
[TBL] [Abstract][Full Text] [Related]
14. CB1 antagonists for obesity--what lessons have we learned from rimonabant?
Di Marzo V; Després JP
Nat Rev Endocrinol; 2009 Nov; 5(11):633-8. PubMed ID: 19844251
[TBL] [Abstract][Full Text] [Related]
15. End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion.
Bifulco M; Pisanti S
Nat Rev Drug Discov; 2009 Jul; 8(7):594. PubMed ID: 19568284
[No Abstract] [Full Text] [Related]
16. Cannabinoid receptor CB1 antagonists state of the art and challenges.
Bifulco M; Santoro A; Laezza C; Malfitano AM
Vitam Horm; 2009; 81():159-89. PubMed ID: 19647112
[TBL] [Abstract][Full Text] [Related]
17. Oleoyl-estrone treatment reduces the volume of white adipose tissue cells in the rat.
Cabot C; Grasa MM; Fernández-López JA; Alemany M
J Physiol Biochem; 2000 Dec; 56(4):369-70. PubMed ID: 11321531
[No Abstract] [Full Text] [Related]
18. [Sleep disorders associated with treatment with rimonabant].
Sempere AP; Giner-Bernabeu JC; Berenguer-Ruiz L; Selles-Galiana MF; Hernandez-Rubio L; Lezcano-Rodas M
Rev Neurol; 2008 Oct 16-31; 47(8):446. PubMed ID: 18937208
[No Abstract] [Full Text] [Related]
19. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.
Bifulco M; Grimaldi C; Gazzerro P; Pisanti S; Santoro A
Mol Pharmacol; 2007 Jun; 71(6):1445-56. PubMed ID: 17327463
[TBL] [Abstract][Full Text] [Related]
20. [The endocannabinoid system and treatment of obesity].
Aronsen L
Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
